\n<\/p>\n
Mordor Intelligence has published a new report on the <\/span>Peptic Ulcer Drugs Market<\/span> offering a comprehensive analysis of trends, growth drivers, and future projections<\/span>\u00a0<\/span><\/p>\n Introduction<\/span><\/b>\u00a0<\/span><\/p>\n The <\/span>Peptic Ulcer Drugs Market<\/span><\/a> is set to see meaningful expansion over the next several years. According to recent findings, the market size stood at approximately <\/span>USD 5.33 billion in 2025, and it is expected to grow to about USD 6.22 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 5.10%.\u00a0<\/span>\u00a0<\/span><\/p>\n This market encompasses treatments used for peptic ulcer disease including gastric ulcers, duodenal ulcers, stress-related mucosal damage, and associated acid-related conditions. Key categories of these drugs include proton pump inhibitors (PPIs), potassium-competitive acid blockers (PCABs), H2 receptor antagonists, antacids, and combinations of therapies, especially for Helicobacter pylori eradication. Regulatory concerns, shifting prescription patterns, and rising demand in emerging regions are influencing how the market develops.\u00a0<\/span>\u00a0<\/span><\/p>\n Key Trends in the Peptic Ulcer Drugs Market<\/span><\/b>\u00a0<\/span><\/p>\n Market Segmentation of the Peptic Ulcer Drugs Market<\/span><\/b>\u00a0<\/span><\/p>\n The Peptic Ulcer Drugs Market can be segmented in several ways, each revealing important dynamics:<\/span>\u00a0<\/span><\/p>\n By Drug Class<\/span><\/b>\u00a0<\/span><\/p>\n By Disease Indication<\/span><\/b>\u00a0<\/span><\/p>\n By Distribution Channel<\/span><\/b>\u00a0<\/span><\/p>\n By Geography<\/span><\/b>\u00a0<\/span><\/p>\n Key Players in the Peptic Ulcer Drugs Market<\/span><\/b>\u00a0<\/span><\/p>\n Several pharmaceutical companies are central to the Peptic Ulcer Drugs Market. They maintain or are expanding their presence through drug development, launches, portfolio diversification, and response to regulatory changes. <\/span>\u00a0<\/span><\/p>\n Market Conclusion<\/span><\/b>\u00a0<\/span><\/p>\n The <\/span>Peptic Ulcer Drugs Market Outlook<\/span><\/a> is broadly positive. Rising prevalence of H. pylori infections, demographic shifts toward older populations, growing awareness of gastrointestinal health, and shifting clinical guidelines around safety are combining to drive change.<\/span>\u00a0<\/span><\/p>\n While PPIs remain foundational, PCABs are likely to capture more share over time as prescribers and patients seek options with fewer limitations. At the same time, distribution methods are evolving, with e-commerce and online pharmacies becoming more significant. Geographic growth in Asia Pacific offers opportunity, particularly in countries investing in healthcare infrastructure and screening programs.<\/span>\u00a0<\/span><\/p>\n Industry Related Reports<\/span><\/b>\u00a0<\/span><\/p>\n Dyspepsia Drugs Market<\/span><\/a>: The Dyspepsia Drugs Market Report is Segmented by Drug Class (Proton Pump Inhibitors, H2 Receptor Antagonists, Prokinetics & Neuromodulators, and More), Route of Administration (Oral Solid, Oral Liquid, and More), Distribution Channel (Online Pharmacy, Retail Pharmacy, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).<\/span> Gastrointestinal Therapeutics Market<\/span><\/a>: The Gastrointestinal Therapeutics Market Report is Segmented by Drug Class (Proton Pump Inhibitors, H2 Receptor Antagonists, and More), Disease Indication (GERD, Peptic Ulcer and More), Route of Administration (Oral, Injectable, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, and More).<\/span> Esomeprazole Market<\/span><\/a>: The Esomeprazole Market Report is Segmented by Dosage Form (Tablets, Capsules, Others), Strength (20 Mg, 40 Mg, Others), Application (Gastroesophageal Reflux Disease, Stomach Ulcers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). <\/span> About Mordor Intelligence:<\/span><\/b>\u00a0<\/span><\/p>\n Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.<\/span>\u00a0<\/span><\/p>\n With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.<\/span>\u00a0<\/span><\/p>\n For any inquiries or to access the full report, please contact:<\/span><\/b>\u00a0<\/span><\/p>\n media@mordorintelligence.com<\/span><\/a>\n
While PPIs retain a large part of the market share (about half in recent years) for peptic ulcer treatment, PCABs are growing significantly faster. Their advantages\u2014faster onset of action, fewer food-timing restrictions, and improved safety in long-term use\u2014are encouraging prescribers and payers to favor them in new treatment protocols.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n\n
Screening programs for H. pylori are expanding, especially in Asia Pacific and other regions with high infection rates. This is contributing to higher demand for combination therapies used to eradicate the bacteria. Such demand also supports uptick in antibiotic regimens and gastro-protective agents.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n\n
Concerns over cardiovascular risks, possible oncologic risks, and other adverse outcomes associated with long-term PPI exposure are influencing clinical guidelines. These concerns are accelerating the shift toward alternatives like PCABs and more restraint in PPI prescribing for maintenance therapy.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n\n
The distribution channel mix is changing. Hospital pharmacies remain strong, but online pharmacies and e-commerce platforms are predicted to grow rapidly, offering patients greater convenience and accessibility. This channel shift is particularly noticeable in markets where digital health infrastructure is improving.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n\n
North America continues to be the largest region by revenue, but Asia Pacific is forecast to register the highest growth rate through 2030. Key factors in Asia Pacific include rising middle-class populations, government-led screening initiatives, and increased branded generics availability.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\u00a0<\/span><\/p>\n
\u00a0<\/span><\/p>\n
\u00a0<\/span><\/p>\n
https:\/\/www.mordorintelligence.com\/<\/span><\/a>\u00a0<\/span><\/p>\n<\/p><\/div>\n